David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Ibrutinib-regimes versus chemo-immuuntherapie bij oudere CLL-patiënten
mrt 2019 | Leukemie, Ouderen